Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a 3-Month TB cocktail replace the standard 6-Month regimen?

NCT ID NCT04311502

Terminated Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This clinical trial investigates whether a 3-month combination of clofazimine and rifapentine can effectively treat drug-susceptible tuberculosis (TB) compared to the standard 6-month regimen. The study includes adults with pulmonary TB, some of whom also have HIV. Researchers are measuring how quickly the bacteria clear from sputum and tracking any serious side effects over 65 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Clofazimine and Rifapentine
What this could lead to
If successful, this could shorten tuberculosis treatment from 6 months to 3 months, making it easier for patients to complete therapy and potentially reducing transmission.
What could go wrong
This is a Phase 2 trial with only 104 participants, so results may not apply to everyone. The shorter regimen may be less effective or cause more side effects than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRUG SUSCEPTIBLE PULMONARY TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease pulmonary tuberculosis tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV TUBERCULOSIS

Contacts and locations

Locations

  • Blantyre CRS

    Blantyre, 1131, Malawi

  • Byramjee Jeejeebhoy Medical College (BJMC) CRS

    Pune, 411001, India

  • CAPRISA eThekwini CRS

    Durban, KwaZulu-Natal, 4013, South Africa

  • Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS

    Port-au-Prince, HT-6110, Haiti

  • Malawi CRS

    Lilongwe, Central Region, Malawi

  • Milton Park CRS

    Harare, Zimbabwe

More trials for these conditions

Other studies related to the condition(s) this trial covers.